Jonas Salk documentary, "Apart from the atomic bomb, America's greatest fear was polio." As a result, scientists were in a frantic race to find a way to prevent or cure the disease. In 1947, Salk accepted an appointment to the University of Pittsburgh School of Medicine. In 1948, he undertook a project funded by the National Foundation for Infantile Paralysis, the organization that would fund the development of a vaccine, to determine the number of different types of polio virus. Salk saw an opportunity to extend this project towards developing a vaccine against polio, and, together with the skilled research team he
SAV001 a feasible option for an HIV vaccine. Indeed, Jonas Salk developed a therapeutic HIV vaccine in 1987, called Remune now being developed by Immune Response BioPharma, Inc., is based on the killed whole virus approach. Remune vaccine has completed over 25 clinical studies to date and showed a robust mechanism of action restoring white blood cell counts in CD4 & CD8 T cells by reducing viral load and increasing immunity. Also, a group of researchers and professionals in the field of HIV strongly advocates that the killed HIV approach must be taken to fight back the global HIV and AIDS